FENC vs LCTX vs SNOA vs HALO vs SUPN

For growth investors, Fennec Pharmaceuticals Inc.

(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Halozyme Therapeutics, Inc.

is actually cheaper at 8. 0x.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to -99. 2% for Sonoma Pharmaceuticals, Inc. (SNOA). Over 10 years, the gap is even starker: HALO returned +559. 7% versus SNOA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Fennec Pharmaceuticals Inc. 's 1. 78β — meaning FENC is approximately 247% more volatile than HALO relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 7% for Sonoma Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.

(FENC) is pulling ahead at 123. 7% versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). On earnings-per-share growth, the picture is similar: Fennec Pharmaceuticals Inc. grew EPS 97. 3% year-over-year, compared to -201. 1% for Lineage Cell Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -436. 5% for Lineage Cell Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -251. 6% for LCTX. At the gross margin level — before operating expenses — LCTX leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 54. 3x for Fennec Pharmaceuticals Inc. — 46. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FENC: 160. 9% to $18. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Fennec Pharmaceuticals Inc. (FENC) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, FENC: -42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FENC is a small-cap high-growth stock; LCTX is a small-cap high-growth stock; SNOA is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.